Saffron Extract Looked Promising for Mood in Women 50-70. The Sleep Claim Is More Complicated

A saffron sleep headline can go wrong in about three words.

The useful finding from the new trial isn’t “saffron fixes sleep.” It doesn’t show that. The better read is narrower: in a small 2026 randomized trial, women aged 50 to 70 with low mood and self-reported poor sleep had bigger improvements in depressive symptoms, self-esteem, and sleep-related impairment after taking a standardized saffron extract called Affron® for 12 weeks. But the same study did not find a significant improvement in sleep disturbance itself. It also didn’t show improvements in self-rated appearance or estimated facial skin age (Frontiers in Nutrition; PubMed).

That’s a lot of caveat for one spice extract. Still, it’s the caveat that makes the study useful.

If you’ve seen saffron marketed for mood, sleep, menopause, beauty, or “healthy aging,” this is exactly the kind of trial that needs a slow read. There is a real mood signal here. There is a much narrower sleep signal. And there is no good reason, based on this trial, to turn saffron into a beauty or skin-aging claim.

One more thing upfront: the product manufacturer, Pharmactive Biotech Products, funded the trial, supplied the products, and was involved in the initial study concept and design. The paper says analyses were conducted independently, but manufacturer funding and design involvement still matter. They don’t erase the results. They do mean the findings should be read with that conflict in mind.

What the study actually tested

#

The trial tested Affron®, a standardized saffron extract, not saffron threads from the kitchen and not any random saffron supplement on a marketplace page. The extract was standardized to compounds called Lepticrosalides®, including crocins and safranal, and participants took the study product daily for 12 weeks. That’s a description of the protocol, not a dose recommendation.

The study included 86 women aged 50 to 70 who reported low mood and poor sleep. It was randomized, double-blind, and placebo-controlled, which is the stronger part of the design. But it was still small and short, and it was limited to a very specific group. So, no, it shouldn’t be stretched to men, younger adults, people with diagnosed major depressive disorder, everyone with insomnia, or all saffron products.

And it wasn’t a menopause trial in the strict sense, either. The participants were women in the 50-70 age range, but the study wasn’t built to prove menopause-specific benefits.

The mood result was the clearest signal

#

On the depression scale used in the study, the saffron group improved more than the placebo group. The paper reported a greater reduction in DASS-21 depression scores, with an adjusted mean difference of 2.37 points, a 95 percent confidence interval from 0.23 to 4.51, Cohen’s d=0.48, and p=0.030 (Frontiers in Nutrition).

That is not a miracle result. It is also not nothing.

Nearly half of the saffron group met the trial’s threshold for a clinically meaningful depressive-symptom improvement, compared with about one quarter of the placebo group: 48.8 percent versus 25.6 percent. Because the measure was self-reported and the trial was small, this shouldn’t be translated into “saffron treats depression.” A safer read is that this particular saffron extract showed a short-term signal for self-reported depressive symptoms in this study population.

That fits reasonably well with the broader natural depression remedies evidence, though not perfectly. A 2026 GRADE-assessed review of 34 randomized trials found saffron improved some self-reported depression and anxiety measures, including BDI and BAI, but not all clinician-rated or other mood scales, including HDRS, HARS, and POMS (PubMed). So the wider evidence is promising, especially around self-reported symptoms, but it isn’t uniformly positive.

The sleep result needs careful wording

#

Here’s where supplement marketing could easily outrun the paper.

The trial did find better sleep-related impairment in the saffron group. In plain English, that points to less daytime trouble linked to sleep - things like functioning, tiredness, or the way poor sleep spills into the day, depending on the questionnaire used.

But the study did not find a significant between-group improvement in sleep disturbance itself. The p value for sleep disturbance was 0.786. That’s not a close call hiding behind cautious language. It’s a reminder that “felt less impaired by sleep problems” is not the same claim as “slept better” or “had less insomnia.”

So what should a reader do with that? I think the honest takeaway is modest: in this study, Affron® looked more relevant to mood and daytime sleep-related impairment than to sleep disturbance as a standalone outcome. If someone turns this into “saffron improves sleep in older women,” they’ve skipped the most important part.

Self-esteem improved, but the beauty claims didn’t land

#

The self-esteem finding is interesting, and maybe clinically relevant if it holds up. The saffron group improved more than placebo on self-esteem, with an adjusted mean difference of 1.43 points and p=0.022 (Frontiers in Nutrition).

But this was a secondary outcome, and the authors noted that secondary measures were exploratory and not adjusted for multiple comparisons. In less tidy language: when a study checks several extra outcomes, some can look positive by chance. That doesn’t make the result fake. It means replication matters.

The trial also looked at self-rated physical appearance and estimated facial skin age. Those did not significantly improve versus placebo. That’s worth saying plainly because “mood, sleep, self-esteem, appearance, skin age” is exactly the kind of bundle that can become a glossy supplement story. The actual paper is less glossy. Mood looked better. Sleep-related impairment looked better. Self-esteem looked better. Appearance and estimated skin age did not.

Safety box: don’t treat saffron like harmless mood candy

#

Safety box: Saffron supplements are not depression or sleep treatments, not medication replacements, and not automatically safe just because saffron is a food spice. Use this section as the pause point before any buying decision.

Before any consumer takeaway, here’s the safety filter.

Saffron supplements are not a replacement for depression care, sleep evaluation, therapy, antidepressants, sleep medicines, hormone therapy, or any clinician-managed treatment. If low mood is persistent, severe, worsening, or tied to self-harm thoughts, mania or hypomania, psychosis, substance use, postpartum symptoms, or major problems functioning, that belongs in medical care now, not in supplement experimentation.

Pregnancy and breastfeeding need extra caution. Food amounts of saffron are one thing; concentrated supplement amounts are another. WebMD warns that larger-than-food amounts during pregnancy are likely unsafe because saffron can make the uterus contract and might cause miscarriage, and breastfeeding safety beyond food amounts isn’t established (WebMD).

People with bipolar disorder or a history of mood cycling should not casually use saffron for mood support. WebMD warns saffron may affect mood and could trigger excitability or impulsive behavior in people with bipolar disorder. That’s not a small footnote if the product is being used for “low mood.”

And if you’re taking sedatives, diabetes medicines, blood-pressure drugs, or regular caffeine, check with a clinician or pharmacist first. WebMD lists cautions around central nervous system slowing, blood sugar, blood pressure, and caffeine breakdown. NCCIH also warns that supplements can interact with medications, pose risks around surgery and anesthesia, and differ from the products used in studies (NCCIH).

Possible side effects include drowsiness, stomach problems, nausea or vomiting, and allergic reactions. High amounts can be dangerous. That’s not a reason to panic about saffron as a spice. It’s a reason not to treat concentrated products as automatically safe because they’re “natural.”

What this means if you’re saffron-curious

#

If you’re looking at saffron because of low mood and poor sleep after 50, the study is worth knowing about - but not worth over-reading.

The most defensible conversation is something like this: “A small trial of a standardized saffron extract in women my age found a mood signal and less sleep-related impairment, but not less sleep disturbance. Does this make sense with my medications, health history, and symptoms?” That is a very different conversation from “Should I take saffron for depression or insomnia?”

The product-specific part matters too. Affron® is not interchangeable with culinary saffron, generic saffron capsules, or multi-ingredient mood/sleep blends. Supplement quality varies, and FDA guidance is clear that dietary supplements are regulated differently from drugs; they are not FDA-approved treatments for depression, insomnia, menopause symptoms, or skin aging (FDA).

So, yes, this trial adds something useful to the saffron conversation. But it adds a precise thing, not a permission slip for broad claims.

Bottom line

#

The new Affron® trial gives saffron a cautious, product-specific mood signal in women aged 50 to 70 with low mood and self-reported poor sleep. It also found improvement in sleep-related impairment and self-esteem.

But the sleep claim needs care. Sleep disturbance itself did not improve significantly versus placebo. Appearance and estimated facial skin age didn’t improve either. The trial was small, short, manufacturer-funded, and limited to a specific population.

So the fairest read is not “saffron works for sleep” or “saffron treats depression.” It’s this: one standardized saffron extract looked promising for self-reported mood symptoms in a small 12-week trial, with a narrower signal for daytime sleep-related impairment - and anyone considering it should treat it like a biologically active supplement, not a harmless spice upgrade.